



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

1619
PATENTS
TECH CENTER 1600/2900
FEB 14 2002
RECEIVED

In re Application of:

Collins et al.

Serial No.: 09/690,198

Filed: October 16, 2000

For: Cobalamin Conjugates Useful as
Imaging Agents and Antitumor Agents

Art Unit: 1619

Examiner: Michael A. Willis

RESPONSE TO RESTRICTION REQUIREMENT AND ELECTION OF SPECIES

Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Restriction Requirement mailed in the above-application on November 27, 2001, Applicants elect claims 1-112 for prosecution, drawn to cobalamin compounds classified in class 514, subclass 52. In response to the election of species requirement, Applicants elect the doxorubicin-cobalamin conjugate described in example 1 of the specification. Claims 1, 3, 5, 7, 9, 12, 13, 14, 15, 18, 20, 24, 49, 50, 51, 55, 56, 60, 61, 111, and 112 read upon the elected species.

Applicants would like to remind the Examiner that upon allowance of a generic claim, Applicants are entitled to consideration of claims to additional species within the limitations of the generic claim.

Enclosed is a petition for one month extension of time and a check in the amount of \$55.00 to cover the extension. To the extent any additional fees are due, please charge deposit account no. 11-0295.

Respectfully submitted,

Clark G. Sullivan
Reg. No. 36,942

King & Spalding
45th Floor, 191 Peachtree Street, N.E.
Atlanta, GA 30303
404.572.4600
K&S Docket: 07959.105025
2262645

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on January 28, 2002.

Clark G. Sullivan, Reg. No. 36,942